Kexing Biopharm

Executive Summary

Kexing Biopharm, a Chinese biopharmaceutical leader, is renowned for its COVID-19 vaccine CoronaVac, which has been widely deployed globally. The company leverages its inactivated virus platform to develop vaccines and biologics addressing hepatitis, influenza, and other infectious diseases. With commercial-stage operations and a strong manufacturing base in Beijing, Kexing continues to invest in R&D to expand its pipeline and adapt to emerging viral threats. Looking ahead, Kexing aims to maintain its momentum by pursuing regulatory approvals for updated COVID-19 vaccines targeting new variants and advancing its influenza and hepatitis vaccine candidates. The company's strategic focus includes securing global partnerships and expanding its presence in international markets, particularly through COVAX and bilateral agreements. Despite competitive pressures and regulatory complexities, Kexing's proven platform and large-scale production capabilities position it for sustained growth in the infectious disease vaccine space.

Upcoming Catalysts (preview)

• Q3 2026Regulatory approval for updated COVID-19 vaccine (variant-adapted)70% success
• Q4 2026Phase 3 data readout for seasonal influenza vaccine candidate60% success
• Q2 2026Expansion of global vaccine supply agreements via COVAX or bilateral deals55% success